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Abstract 
Tumor suppressor p53 is a transcription factor that is central to a system of cell cycle regulation 
and the prevention of cancer. The C. elegans p53 homolog CEP1 is more stable than human p53. 
It has been hypothesized that this is due in large part to a specific segment known as the S7S8 
turn. The S7S8 turn is ten residues in human p53 but the analogous structure is only six amino 
acids in C. elegans p53. Because the turn is shorter and likely less flexible in C. elegans p53 than 
in human p53, it is hypothesized that this elongated turn in human p53 lends to increased 
movement and instability. Therefore, shortening the S7S8 turn in p53 might stabilize the turn and 
the entire protein. In addition to the S7S8 turn, a focus of this research is centered on 
understanding the effects of adding an N-terminal extension to the core domain of p53. This 
segment was initially added for the purpose of reducing aggregation. However, initial 
experiments suggest that this segment might also affect stability and function. Two sets of a 
panel of eight turn variants with differing sizes and physical properties were synthesized to 
compare the variants with the N-terminal extension and the ones without it. The Magliery lab has 
developed a screen which tests the DNA-binding ability of p53. The screen was made with green 
fluorescent protein that is negatively suppressed in the presence of active p53 protein. Because 
none of the mutations made to our p53 mutants are in the DNA-binding region, it is hypothesized 
that any variation in fluorescence is due to differences in stability. Western blots were performed 
to further probe the screen and test this hypothesis. Finally, circular dichroism, differential 
scanning fluorimetry, and thermal melts were used to distinguish biophysical differences 
between various turn mutants with and without the N-terminal extension. 
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Introduction 
A brief history of p53 and cancer 
The history of cancer research is long. In the 1860s, Virchow identified the connection between 
cancer cells and increased inflammation1. In the 1950s, Otto Warburg theorized that it was a 
change from cell respiration to fermentation that caused cancer cells2. Monumental discoveries 
of the importance and structure of DNA led to the modern consensus that tumorigenic cells are 
initiated by DNA mutation. In 2012, GLOBOCAN estimated that there about 14.1 million new 
cancer patients and 8.2 million deaths worldwide3. 
 
Figure 1: The six hallmark capabilities of cancer4. Tumor suppressor p53, when functional, can 
prevent a cancerous cell from replicating or can cause apoptosis. 
p53 was first identified in 1979 and then classified as an oncogene or a cancer-causing agent5. It 
was later theorized that p53 was a tumor suppressor. The fact that p53 protein was found to be 
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functional in healthy cells while dysfunctional in cancer cells, through protein unfolding or an 
inability to bind to DNA, supported the second theory. It has recently been shown that the truth 
lies somewhere between these two theories. Healthy p53 protein does appear to function as a 
transcription factor and tumor suppressor6. However, some mutant p53 proteins have been shown 
to be carcinogenic themselves7, 8, 9.  
 
Figure 2: p53 research timeline10. Pink: early steps in understanding p53 function (1979-1988). 
Blue: p53 as a tumor suppressor and transcription factor, protecting against oncogenic DNA 
damage (1988-1994). Green: current research focusing on p53 mutations in cancer and 
development of drugs targeting p53 (1995-present). Purple: projected applications of p53 
research to cancer diagnosis and treatment. 
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Loss of function of tumor suppressor p53 opens the door for carcinogens to alter a cell’s DNA 
towards a cancerous state. p53 mutations can also lead to gain of function of oncogenic 
properties, but this is not necessarily true (in fact, it may be rare). 
 
Figure 311: A list of stressors that cause p53 to respond. These signals usually lead to 
stabilization of p53 protein, which leads to an increase in cellular p53 levels. The effect of p53 
activation is generally to inhibit cell growth, but cell-cycle arrest or induction of apoptosis can 
also occur in order to prevent tumor development. 
Upon reading any scientific paper on tumor suppressor p53, one would have to struggle to find a 
paper that does not include the fact that “mutated p53 is found in more than half of all human 
cancer” and the phrase “guardian of the human genome”10, 12. Tumor Suppressor p53 is referred 
to as the guardian of the human genome because it is viewed as central to the cell’s defense 
mechanisms to prevent cancer development. In my opinion, p53 has been recognized as the 
guardian of the human genome thanks to a paradox. Rather than being a strong link and 
dependable protein (as the word guardian would suggest), p53 tends to fail so that it is often the 
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cause of the breakdown of the cell’s defense mechanism. In fact, the p53 gene is the most 
frequently mutated gene in human cancer13. This is because p53 has evolved to be an inherently 
unstable protein14-15. Singular mutations, such as V143A, R175H, and R273H destroy its 
functionality16. This is why it is our goal to discover a method to raise the stability of the p53 
protein. How this is done is the focus of this research. 
 
Figure 417: The most common p53 missense mutation in human tumors. About 95% percent of 
the mutations lie within the core DNA-binding domain18 (Brown et al – 2009). 75% of these 
mutations are missense mutations. 
Tumor Suppressor p53 works among a system of factors, such as MDM2 and MDM4, which 
influence gene transcription19. When activated, p53 prevents cancer development via DNA 
repair, senescence, or apoptosis20. 
 
S7S8 Turn 
The Nussinov lab conducted molecular dynamics simulations, comparing human p53 protein to 
its homolog in Caenorhabditis elegans. The simulations predicted that the worm’s p53 homolog 
(Cep-1) was more stable than human because of three major differences: Loop L1, the turn 
between helix H1 and beta-strand S5, and the S7S8 Turn. Loop L1 lacks secondary structure and 
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both turns are much longer in the human p5321. The Nussnov lab designed a mutant by 
shorteninh the S7S8 turn and predicted that shortening the S7S8 turn should create not only a 
more stable S7S8 turn, but a more stable p53 protein overall. The goal of my research is to 
explore this hypothesis by creating several S7S8 turn mutants and compare their stability to the 
wild type p53 protein. 
  
Figure 521: Ribbon representations of crystal structures  
2A: human p53 core domain; 2B: Caenorhabditis elegans homolog – Cep1.  
This research focuses on the differences between the S7S8 turn in human p53 and its shorter and 
less flexible analogous structure in Cep1. 
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Figure 622: p53 core domain structure.  
6A: Ribbon diagram of DNA-free p53 core domain  
6B: Ribbon diagram of p53 core domain bound to consensus DNA. Residues that contact DNA 
are shown as sticks, and mutation sites shown in space-filling representation. 
Figure 5B is a good representation of how the p53 protein interacts with DNA as a transcription 
factor. Note that the S7S8 turn (at the bottom right of the diagram, colored green) is located 
away from the DNA. This is important when it comes to both stabilizing p53 and the screen 
created by the Magliery lab23. According to the Nussinov lab’s simulations, the three regions that 
one could target to stabilize p53 would be the L1 loop, S7S8 turn, and H1S5 turn21. The Fersht 
lab demonstrated that stabilizing the L1 loop can stabilize p5324. The S7S8 turn, however, is 
further away from the DNA binding region of the protein so the turn can be altered without 
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impacting DNA binding as much as altering the L1 loop would. This is a strong reason for 
focusing on stabilization of the S7S8 turn to increase the overall stability of p53 rather than the 
L1 loop or H1S5 turn. In regards to the Magliery lab screen, it tests for DNA binding, not 
stability. However, because the changes to our S7S8 turn variants should not impact DNA 
binding, the only differences seen should reflect changes in stability (note: it could be affected by 
aggregation, which would be clearer with a Western Blot). 
 
Figure 725: This urea melt originated in an instrumental paper in the Fersht lab. It demonstrated 
that the p53 core domain could be stabilized by mutations in general and four specific ones – 
M133L, V203A, N239Y, N268D – in particular. The p53 protein with these four mutations is 
known as the Quadruple mutant, or Quad for short. 
 
N-Terminal Extension            
In 2011 the Fersht lab made a finding concerning an N-terminal extension to the core domain of 
human p53. p53 protein aggregates rapidly which can render protein analysis difficult, which is 
why it was a welcome sign to find that adding an extension of five residues (sequence: PSWPL) 
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onto the N-terminus of the DNA-binding domain of p53 greatly reduces aggregation26. The N-
terminal extension reduces aggregation by capping a hydrophobic patch that was previously 
exposed to solvent. This is mainly due to a cation-Pi interaction of indole ring of Trp91 with the 
guanidinium group of Arg174. With this knowledge, we double are library of mutants to include 
both variants with and without the N-terminal extension. The goal is to measure if the N-terminal 
extension improves stability of the core domain in addition to reducing aggregation. 
 
Figure 826: Simulation of the N-terminal extension to the DNA-binding domain of p53 and how 
it acts as a caps a hydrophobic patch. 
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Figure 926: Light scattering for various forms of p53. Increased light scattering indicates 
aggregation, so the marked decrease in aggregation from p53 (94-312) when adding the N-
terminal extension for p53 (89-360) was a large impetus to adding the N-terminal extension to 
our variant.  
In addition to reducing aggregation, the Fersht lab found that addition of the N-terminal 
extension raised the melting temperature of the core domain (89-293 vs 94-312) by 0.6 oC and 
raised the tetrameric p53 variants (residues 89-360 vs 94-360) by 2 oC. From these data, they 
concluded that the p53 DNA-binding domain is thermodynamically stabilized by the N-terminal 
extension. Our goal is to evaluate this claim that the N-terminal extension improves stability of 
the core domain. 
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Materials and Methods 
Creation of Mutants 
Name S7S8 Turn Sequence 
Human YEPPEVGSDC 
Cep1 MYPGA----V 
AGSG YA----GSGC 
EASA YE----ASAC 
ESE YE-----SEC 
ESG YE-----SGC 
EGE YE-----GEC 
EGSG YE----GSGC 
EGSD YE----GSDC 
ESD YE-----SDC 
 
Table 1: Table of p53 S7S8 turn mutants and their sequences 
*Note: This is not really the S7S8 turn in Cep1; however, it is the homologous structure. 
Previous efforts in the Magliery lab were made to shorten the S7S8 turn in order to stabilize p53. 
These efforts include a complete removal of the turn and a transplant of the Cep1 sequence into 
p53 but neither was successful27. It was decided to shorten the turn to mimic the length of the 
analogous structure to the S7S8 turn in Cep1 and maintain the charged amino acids (Glutamate 
and Aspartate) due to the turn’s solvent exposure and Glycine for geometrical reasons. 
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In addition to the S7S8 turn mutants in the table above, a series of negative mutants were created 
for screening and expression. They include V143A, R175H, E224Q, R249S, and R273H.  
 
Figure 10: Plots the different effects the mutations have on p53’s stability and binding affinity16. 
The mutants we cloned were chosen for their various effects, mostly negative. It is important to 
point out that if we are successful in stabilizing p53 by shortening and stabilizing the S7S8 turn, 
it would be a good target for mutants which have moderate DNA-binding affinity but reduced 
stability (e.g. V143A). However, it would not rescue mutants affecting DNA binding (e.g. 
R273H) or the Zn2+ region (e.g. R175H). 
Cloning of Mutants 
Mutants were cloned using Polymerase Chain Reaction. Conditions were optimized with 
recombinant Pfu polymerase. Mutagenic primers were ordered from Sigma Genosis and pre-
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existing templates of p53 were used for mutagenesis. Potential contaminants were removed from 
PCR products via chloroform and ethanol extraction. To clone into the screening vector, 
pACBAD, PCR products were digested with restriction enzymes BamHI and BsrGI, and to clone 
into the expression vector, pHLIC, PCR products were digested with NcoI and XhoI. These 
digested inserts were purified with QIAQuick gel extraction and were then ligated at 16 oC 
overnight with the digested pACBAD vector for the screening strains and with digested pHLIC 
vector for the expression strains. The ligations (1 µL) were transformed into electrocompetent 
DH10β cells (30 µL), recovered for an hour and plated to the appropriate antibiotic plate. Single 
colonies were selected and grown to saturation, and the DNA was extracted, analyzed by 
restriction enzyme digest, and confirmed by DNA sequencing.  
 
Step Temperature Time Number of Cycles 
Initial Denaturation 95 oC 2 min 1 
Denaturation 95 oC 30 s  
25 Annealing 55 oC 30 s 
Elongation 72 oC 1 min 
Final Extension 72 oC 5 min 1 
Soak 4 oC N/A 1 
Table 2: PCR Scheme 
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Screening 
Brinda Ramasubramanian, a previous member of the Magliery lab, created an in vivo screen for 
functionality. The pACBAD p53 variants were co-transformed into DH10β electrocompetent 
cells with Green Fluorescent Protein and plated on LB Kan Amp plates for selection of single 
colonies. Colonies were selected, grown in 2YT to saturation, and plated on LB Kan Amp plates 
with 0.005% arabinose to induce p53 production. Fluorescence was measured with UV light 
after 48 hours of incubation at 37 oC. Phenotypes were classified as passing the screen if the 
colonies were dark, failing the screen if the colonies were bright, and intermediate if their 
brightness was mediated. 
 
Figure 11: Schematic of cell-based screen created by Brinda Ramasubramanian. Cells will only 
pass the screen when p53 is active and bound to DNA, blocking the RNA polymerase’s 
trajectory. If the p53 is stable but it does not bind, the colony will fluoresce. Or if the p53 is not 
stable, it will not bind to DNA and the colony will fluoresce. 
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Expression and Purification 
After the variants were cloned into pHLIC and transformed into C41(DE3) cells, 25 mL seed 
cultures were grown overnight with Ampicillin. The seed was used to inoculate 1L of 2YT media 
(16 g tryptone, 10 g yeast extract, 5 g NaCl, 1 L H2O), grown to OD600 0.6-1.0 and then induced 
with 0.2 mM IPGT (200 µL). The cultures were then grown for 16 hours at 25 oC then 
centrifuged at 5000 rpm for 10 minutes to create cell pellets and were frozen at -20 oC. The 
pellets were thawed and dissolved in 25 mL of lysis buffer (50 mM Tris-HCl pH 7.4, 300 mM 
NaCl, 10 mM imidazole, 100 µM ZnCl2, 15 mM β-mercaptoethanol) at 4 oC. Once the mixture is 
homogeneous, the following were added on ice and incubated for 45 minutes: 1 mM PMSF 
(Phenyl-methyl-sulfonyl-flouride – 150 µL of 200 mM), 5 mM MgCl2 (75 µL of 2 M MgCl2), 
0.5 mM CaCl2 (15 µL of 1 M Ca Cl2), DNase I (5 µL of 5 mg/mL), RNase A (5 µL of 10 
mg/mL), and 10% Triton X-100 (300 µL). PMSF is needed as a protease inhibitor so the p53 
protein does not degrade and the salts work as coenzymes for DNase I. Triton X-100 is a 
detergent used to solubilize proteins. The cells were lysed open by passing them through an 
Emulsiflex twice. The solution was then centrifuged at 15000 rpm for 1 hour (2x 1/2 hour spins) 
to retrieve the soluble p53 protein in the supernatant while the pellets were discarded. The 
supernatant was bound to Ni2+-NTA resin (1 mL was buffer swapped into phosphate buffer) for 
1 hour at 4 oC and then run through a large, pre-fitted column (BioRad).  The column was 
washed with 6 mL lysis buffer containing 15 mM imidazole into 6 mL of p53 storage buffer 
(ingredients), then was washed with wash buffer, which was lysis buffer with 30 mM imidazole, 
and then with elution buffer, which was lysis buffer with 250 mM imidazole. The p53 protein 
was mostly in the first wash with lysis buffer. TEV protease was added at 16 oC repeatedly until 
SDS-PAGE gel indicated that the 6x His-tag had been cleaved. The solution was then re-bound 
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to Ni2+-NTA resin (1 mL buffer swapped into phosphate buffer) and run through a column where 
the p53 protein would be in the flow through. 
 
Biophysical Characterization 
Differential Scanning Fluorimetry  
19 µL of p53 protein samples were mixed with 1 µL of the diluted SYPRO Orange dye 
(Invitrogen) (provided as 5000x, diluted to 300x before addition, and then to 15x in the mixture) 
in 96-well thin-wall PCR plates (USA Scientific) and sealed with Adhesive PCR Film (Thermo 
Scientific). Using a BioRad C1000 Thermal Cycler, the temperature, starting at 12.5 oC, was 
increased by 0.2 oC every 12 seconds to acquire thermal denaturation curves. 
Circular Dichroism  
Data were collected on a Jasco J-815 CD spectrometer. Purified p53 protein samples were 
concentrated to 50 µM and any DTT was removed and replaced with TCEP by dialysis.  For 
thermal denaturation, ellipticity was monitored at 222 nm with temperatures rising from 20 to 95 
oC. Six samples were run for each p53 variant and the average melting temperature was 
recorded. 
Western Blot 
A 12.5% SDS-PAGE gel was run with rainbow ladder. The gel was then placed into a sandwich 
within a clamp in the following order: sponge – paper – gel – PVDF membrane – paper – 
sponge. The sandwich was made under Towbin buffer (25 mM Tris, 192 mM Glycine, 0.1% 
SDS, 10% Methanol) to and squeezed tightly to prevent air bubbles from forming. The sandwich 
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was transferred to a Western Blot transfer container and was filled with Towbin buffer and a 200 
V current was applied for 80 minutes, making sure that the current was in the direction of leading 
the protein from the gel towards the PVDF membrane. An ice pack was placed in the container 
to prevent overheating and was replaced with a fresh ice pack if necessary. The membrane was 
removed from the sandwich and was washed with TBST (Tris Buffered Saline Tween – 25 mM 
Tris, 0.15 M NaCl, 0.05% Tween) for 10 min. The membrane was blocked for 1-2 hours with 30 
mL 1% BSA (30 mL TBST + 0.3 g BSA) at room temperature. The membrane was then washed 
with TBST 2X 10 minutes.  
The PVDF membrane was bound to the primary antibody (1:175 dilution – 30 mL TBST + 170 
µg Pab240) overnight at 4 oC. Pab240 is a mouse monoclonal IgG1 that targets residues 212-217 
on the S7 strand28 (Santa Cruz Biotechnology – catalog #sc-99; Friedler et al – Structural 
Distortion of p53). 
The following morning the primary antibody was collected, as it can be used up to ten times, and 
the membrane was washed 2X 10 minutes with TBST at room temperature. Then the membrane 
was bound to the secondary antibody (1:500 dilution – 30 mL TBST + 60 µg secondary 
antibody) and incubated for 1 hour before washing again with TBST 2X 10 minutes. The 
secondary antibody was a goat anti-mouse IgG-HRP (Santa Cruz Biotechnology – catalog #sc-
2005). The Western was visualized via chemiluminesence and DAB.  
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Results 
Cloning 
Cloning of p53 was done with largely the same protocol as used by Ely Porter (Porter 2009) 
A hurdle in my first year was finding the correct PCR conditions for cloning into pACBAD. The 
two agarose gels demonstrate how the denaturation and annealing temperatures were found. 
 
Figure 12: Agarose gel of PCRs with differing denaturation temperatures. 
 27 
 
 
Figure 13: Agarose gel of PCRs with differing annealing temperatures. 
PCR of p53 inserts 
Figure 11 shows that 95 oC was the optimal denaturation temperature for PCR with pfu 
polymerase. Figure 12 illustrates that 63 oC and below was preferable as annealing temperatures 
for PCR with pfu polymerase. Temperatures that were too low were avoided in effort to prevent 
creation of unwanted side products. The general scheme used 50 oC as the annealing 
temperature, but if the PCR was unsuccessful, a gradient spanning 40-60 oC  was introduced. 
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Figure 14: This agarose gel contains S7S8 turn mutant inserts after PCR and chloroform 
extraction. The insert is seen around the 500 bp band and the byproducts below were removed in 
QIAQuick gel extraction. 
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Enzyme Digest 
 
Figure 15: Plasmid map of pACBAD N-terminal Quad stuffer with BsaI and BsrGI cut sites. One 
key difference between cloning into pACBAD vs pHLIC is that the N-terminal extension is 
located within the vector for pACBAD while the extension is located within the insert for 
pHLIC. 
 
Figure 16: The agarose gel has the S7S8 turn mutant inserts after they were digested with BsaI 
and BsrGI for four hours and were purified by QIAQuick gel extraction. 
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Analytical Digest 
 
Figure 17: Plasmid map of p53 in pACBAD analytically digested with PsiI and XhoI. 
 
Figure 18: The agarose gel shows N-terminal EASA, EGE, EGSD, ESD, ESE, and ESG 
pACBAD mutants digested with PsiI and XhoI, resulting in two cuts. If the ligations had been 
unsuccessful, there would only be one band because there would be no PsiI site. After successful 
analytical digests such as this, variants were confirmed with DNA sequencing. 
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Cloning into pHLIC 
Cloning variants into pHLIC was a very similar process to cloning into pACBAD. The only 
differences were to clone using diferent primers and digest with BamHI and NcoI. 
Screen 
 
Figure 19: A picture under UV-light of a cell-based screen containing several variants of p53 
with shortened S7S8 turns along with numerous controls. Saturated cultures were diluted from 
10-2 to 10-6. 
The screen was done using double transformed DH10β cells with the p53 variant in pACBAD 
and GFP. The top half of the screen has all of the variants without the N-terminal extension and 
the bottom half has the variants with the N-terminal extension (Cep1 is the exception because it 
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does not have an N-terminal extension). Two variants clearly fail the screen: Wild Type p53 and 
R175H, both with and without the N-terminal extension. The fact that R175H fails is no surprise 
because mutation destabilizes Wild Type by more than 3 kcal/mol; however, it is surprising that 
Wild Type fails the screen, even with the extension. The Quad mutant passes the screen with and 
without the N-terminus and Cep1 passes too. The remainder of the variants – the six S7S8 turn 
mutants tested – all appear intermediate without the N-terminus and all pass the screen with the 
N-terminus. 
Protein Expression and Purification 
 
Figure 20: A 12.5% SDS-PAGE gel of two variants of p53 protein. 
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Biophysical Characterization 
Biophysical characterization of N-minus Quad was performed by David Bowles. 
 
Figure 21: Circular Dichroism 
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Figure 22: Thermal melt using circular dichroism at 222 nm 
 
Figure 23: Thermal melt using Differential Scanning Fluorimetry 
p53 Variant N-minus CD Tm N-terminal CD 
Tm 
N-minus DSF 
Tm 
N-terminal DSF 
Tm 
WT 38.4 37.4 36.7 35.3 
Quad 43.6 43.8 39.7 40.0 
ESE In Progress 39.6 In Progress 35.6 
E224Q 45.3 41.6 47.2 40.3 
Table 3: Table of Thermal Melt temperatures from CD and DSF 
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p53 Variant S7S8 Sequence 
N-minus Screen 
Activity 
N-terminal Screen 
Activity 
WT YEPPEVGSDC Inactive Inactive 
Cep1 MYPGA----V Active N/A 
Quad YEPPEVGSDC Active Active 
R175H YEPPEVGSDC Inactive Inactive 
AGSG YA----GSGC Intermediate Active 
EASA YE----ASAC Intermediate Active 
EGE YE-----GEC Intermediate Active 
EGSD YE----GSDC Intermediate Active 
ESD YE-----SDC Intermediate Active 
ESE YE-----SEC Intermediate Active 
ESG YE-----SGC Intermediate Active 
EGSG YE----GSGC Intermediate Active 
Table 4: Summary of screen with GFP 
*Cep1 does not have an S7S8 sequence; the sequence listed is its homologous region. R175H, 
like the S7S8 turn mutants, is made in the context of the Quad p53 mutant, which has the 
following mutations – M133L, V203A, N239Y, and N268D. 
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Western Blot 
 
 
Figure 24: Western Blot with p53 purified protein 
In order to evaluate if the Western Blot could be used, it was decided to use purified p53 protein 
for an initial Western Blot. Even though the ultimate goal of the Western is to detect variations 
of p53 protein in the screening vector and would have to be done with cell lysate, this Western 
Blot was used with purified protein to get a better sense if the Pab240 antibody would be 
applicable. These results, while giving a clearer image of the purified p53 protein (the bottom 
row on the membrane) were discouraging due to the high amount of background at the top of the 
membrane and the weak binding at lower concentrations. After this Western, the plan was to do 
one more Western Blot with much more primary antibody and more washes to improve binding 
and reduce background. If the results did not improve, it was thought that a flag tag could be 
used instead. 
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Figure 25A: Western Blot with purified N-terminal E224Q p53 protein on left and N-minus EGE 
p53 lysate on right 
Figure 25B: Corresponding SDS-PAGE gel  
While a 1:1000 dilution was used for the Pab240 primary antibody in the first two Western 
Blots, this Western had a 1:175 dilution, using 170 µg of antibody. Both purified p53 and lysate 
were used on this Western. A protein gel with equal amounts of protein is shown on the right. 
The left half of the protein gel was run with a serial dilution of purified N-terminal E224Q p53 
and the right half was a serial dilution of N-minus EGE lysate. One complication faced in this 
Western was that the electrophoresis could only run at 150 V so it was run for 90 minutes instead 
of 80 minutes. Another problem was that the visualization was difficult to due malfunction in the 
Typhoon; this is why the picture is blurry. That being said, the Western worked well as a 
diagnostic tool. At first it was worrisome that there was a lot of white space for the purified p53, 
just as there was in the first Western; there was also more background above. However, when we 
realized that the white represented superfluous binding by the antibody, all three Westerns 
become much clearer. It then appeared that the background in the upper left of the membrane 
A B 
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could actually be oligomers – dimers, trimers, etc. of amyloid p53. It was also encouraging that 
the lysate was clearly visible on the Western, even at lower concentrations. Based upon this 
result, it was decided to run another Western with several variants of p53 lysate, including wild 
type, Quad, Cep1, ESE, and R175H (all with N-terminal and N-minus). The amount run was be 
based upon the lysate lanes in this Western. In addition, the Western was run with DAB, a 
browning agent, instead of chemiluminescence.  
 
 
Figure 26: Western Blot with DAB 
The Western was much easier to visualize with DAB than with chemiluminescence. It is 
advisable to stick with DAB for the future. This Western demonstrates that there is much more 
p53 protein present in the N-terminal variants of the screen (except for R175H), which helps 
explain why they pass the screen better in the S7S8 turn variants with the extension. 
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Conclusion 
By the end of my research, three distinct questions had formed.  
1. Can altering the S7S8 turn stabilize p53? 
2. What is the effect of the N-terminal extension on the DNA-binding domain of p53?  
3. Can we further characterize the screen? 
S7S8 turn 
The fact that we have created stable p53 mutants by shortening the S7S8 turn is encouraging. 
The mutants all appear intermediate on the screen without the N-terminal extension and then 
pass with the extension. CD spectrum and DSF of N-terminal ESE illustrate that it has similar 
unfolding curves to Quad and Wild Type p53. While I have created eight S7S8 turn mutants by 
shortening the turn by four or five residues, David Bowles has created a library of mutants in an 
effort to find the most stable mutants that pass our screen. Hopefully it will provide a number of 
more stable p53 variants. 
 
N-terminal extension 
Results on the effect of the N-terminal extension on p53 stability are a little unclear. On the one 
hand, the addition of the N-terminus raises the activity of all of the S7S8 turn mutants in the 
screen. On the other hand, the extension has not showed increase stability by any of the 
biophysical characterization methods. At this time, I would confidently say that the N-terminal 
extension does not increase the stability of the core domain. 
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Still, adding the N-terminal extension to our variants was very helpful. The main challenge in 
characterizing p53 variants is aggregation. When some of the proteins were being purified, they 
would aggregate immediately after adding lysis buffer. This was especially significant for the N-
minus variants. One of the best techniques was to elute the protein into as much as 20 mL of p53 
storage buffer because aggregation is dependent on concentration, temperature, and time. At 
first, Amicon tubes were centrifuged to concentrate the p53, but it had to be done at a low rpm 
and took a long time as a result. We switched to using Vivapores and aquicide (a much more 
cost-efficient method) for concentration. Both methods worked very well to quickly concentrate 
the p53 protein before analysis. In addition, the variants with the N-terminus went much longer 
without aggregating than the N-minus variants. While it may be unsatisfying that the N-terminal 
extension does not increase the core domain’s stability, it can be a positive thing to know that the 
extension can be added to prevent aggregation without worry of affecting the dynamics of the 
protein. 
Screen 
There are a few questions surrounding the screen. Why doesn’t Wild Type p53 pass (with or 
without the N-terminal extension)? Why does the addition of the N-terminal extension raise all 
of the S7S8 turn mutants from intermediates to clearly passing the screen? What precisely is the 
dynamic range of the screen? 
These questions were attempted to be answered with Western Blots containing lysate from the 
same cultures that were plated on the screen. This was a challenge because p53, which we 
usually purify with a His-tag, does not have the tag in pACBAD so it cannot be purified. 
Therefore, the lysate must be run on the Western instead of purified protein.  
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